Benzinga
Benzinga
Benzinga
lunedì, settembre 14

CRISPR Therapeutics AG

CRSPNASDAQ
Trade with Public
Trade with Public
$52.96
1.242.4%
In chiusura: Sep 14, 5:00 PM EST
$52.60
-0.36-0.68%
Post-mercato: 4:32 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

CRISPR Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for CRISPR Therapeutics (CRSP).

Price Target Range — 12 Quarters

Analyst Consensus — 23 Analysts

2S.Buy
11Buy
9Hold
1Sell
Consensus RatingBuy# Analysts23Avg. Consensus PT$72Upside to Avg. PT+37.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Aug 31, 2026CitizensSilvan TurkcanMaintainedMarket Outperform$80
Aug 31, 2026NeedhamGil BlumMaintainedBuy$82
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target

Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $82 price target.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88

Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved